144 related articles for article (PubMed ID: 30378165)
1. A systematic review of observational studies of the association between pioglitazone use and bladder cancer.
Ripamonti E; Azoulay L; Abrahamowicz M; Platt RW; Suissa S
Diabet Med; 2019 Jan; 36(1):22-35. PubMed ID: 30378165
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone prescription increases risk of bladder cancer in patients with type 2 diabetes: an updated meta-analysis.
He S; Tang YH; Zhao G; Yang X; Wang D; Zhang Y
Tumour Biol; 2014 Mar; 35(3):2095-102. PubMed ID: 24092576
[TBL] [Abstract][Full Text] [Related]
3. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies.
Ferwana M; Firwana B; Hasan R; Al-Mallah MH; Kim S; Montori VM; Murad MH
Diabet Med; 2013 Sep; 30(9):1026-32. PubMed ID: 23350856
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.
Tang H; Shi W; Fu S; Wang T; Zhai S; Song Y; Han J
Cancer Med; 2018 Apr; 7(4):1070-1080. PubMed ID: 29476615
[TBL] [Abstract][Full Text] [Related]
5. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis.
Zhu Z; Shen Z; Lu Y; Zhong S; Xu C
Diabetes Res Clin Pract; 2012 Oct; 98(1):159-63. PubMed ID: 22705039
[TBL] [Abstract][Full Text] [Related]
6. Study design choices for evaluating the comparative safety of diabetes medications: An evaluation of pioglitazone use and risk of bladder cancer in older US adults with type-2 diabetes.
Garry EM; Buse JB; Gokhale M; Lund JL; Nielsen ME; Pate V; Stürmer T
Diabetes Obes Metab; 2019 Sep; 21(9):2096-2106. PubMed ID: 31087620
[TBL] [Abstract][Full Text] [Related]
7. Pioglitazone and bladder cancer in human studies: is it diabetes itself, diabetes drugs, flawed analyses or different ethnicities?
Tseng CH
J Formos Med Assoc; 2012 Mar; 111(3):123-31. PubMed ID: 22423665
[TBL] [Abstract][Full Text] [Related]
8. The impact of pioglitazone on bladder cancer and cardiovascular events.
Lee EJ; Marcy TR
Consult Pharm; 2014 Aug; 29(8):555-8. PubMed ID: 25203263
[TBL] [Abstract][Full Text] [Related]
9. A word of caution regarding pioglitazone.
Usman MS; Rizwan T; Ahmed F
J Pak Med Assoc; 2017 Jan; 67(1):153. PubMed ID: 28065979
[No Abstract] [Full Text] [Related]
10. Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.
Qu H; Zheng Y; Wang Y; Zhang R; Ruan X; Yang G; Liu Z; Zheng H
Sci Rep; 2017 Nov; 7(1):15804. PubMed ID: 29150684
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.
Levin D; Bell S; Sund R; Hartikainen SA; Tuomilehto J; Pukkala E; Keskimäki I; Badrick E; Renehan AG; Buchan IE; Bowker SL; Minhas-Sandhu JK; Zafari Z; Marra C; Johnson JA; Stricker BH; Uitterlinden AG; Hofman A; Ruiter R; de Keyser CE; MacDonald TM; Wild SH; McKeigue PM; Colhoun HM; ;
Diabetologia; 2015 Mar; 58(3):493-504. PubMed ID: 25481707
[TBL] [Abstract][Full Text] [Related]
12. Association between pioglitazone use and the risk of bladder cancer among subjects with diabetes mellitus: a dose-response meta-analysis
.
Li Z; Sun M; Wang F; Shi J; Wang K
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):210-219. PubMed ID: 28025963
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study.
Neumann A; Weill A; Ricordeau P; Fagot JP; Alla F; Allemand H
Diabetologia; 2012 Jul; 55(7):1953-62. PubMed ID: 22460763
[TBL] [Abstract][Full Text] [Related]
14. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study.
Azoulay L; Yin H; Filion KB; Assayag J; Majdan A; Pollak MN; Suissa S
BMJ; 2012 May; 344():e3645. PubMed ID: 22653981
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.
Lewis JD; Habel LA; Quesenberry CP; Strom BL; Peng T; Hedderson MM; Ehrlich SF; Mamtani R; Bilker W; Vaughn DJ; Nessel L; Van Den Eeden SK; Ferrara A
JAMA; 2015 Jul; 314(3):265-77. PubMed ID: 26197187
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis confirms raised risk of bladder cancer from pioglitazone.
Kermode-Scott B
BMJ; 2012 Jul; 345():e4541. PubMed ID: 22763399
[No Abstract] [Full Text] [Related]
17. Proteinuria testing among patients with diabetes mellitus is associated with bladder cancer diagnosis: potential for unmeasured confounding in studies of pioglitazone and bladder cancer.
Lewis JD; Habel L; Quesenberry C; Mamtani R; Peng T; Bilker WB; Hedderson M; Nessel L; Vaughn DJ; Strom BL; Ferrara A
Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):636-45. PubMed ID: 24764283
[TBL] [Abstract][Full Text] [Related]
18. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes.
Fujimoto K; Hamamoto Y; Honjo S; Kawasaki Y; Mori K; Tatsuoka H; Matsuoka A; Wada Y; Ikeda H; Fujikawa J; Koshiyama H
Diabetes Res Clin Pract; 2013 Feb; 99(2):e21-3. PubMed ID: 23228390
[TBL] [Abstract][Full Text] [Related]
19. Comparative safety of pioglitazone versus clinically meaningful treatment alternatives concerning the risk of bladder cancer in older US adults with type 2 diabetes.
Garry EM; Buse JB; Lund JL; Pate V; Stürmer T
Diabetes Obes Metab; 2018 Jan; 20(1):129-140. PubMed ID: 28661561
[TBL] [Abstract][Full Text] [Related]
20. Impact of regulatory spin of pioglitazone on prescription of antidiabetic drugs among physicians in India: A multicentre questionnaire-based observational study.
Goyal A; Singh H; Sehgal VK; Jayanthi CR; Munshi R; Bairy KL; Kumar R; Kaushal S; Kakkar AK; Ambwani S; Goyal C; Mazumdar G; Adhikari A; Das N; Stephy DJ; Thangaraju P; Dhasmana DC; Rehman SU; Chakrabarti A; Bhandare B; Badyal DK; Kaur I; Chandrashekar K; Singh J; Dhamija P; Sarangi SC; Gupta YK
Indian J Med Res; 2017 Oct; 146(4):468-475. PubMed ID: 29434060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]